<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03003559</url>
  </required_header>
  <id_info>
    <org_study_id>2016YFC1304304-1</org_study_id>
    <nct_id>NCT03003559</nct_id>
  </id_info>
  <brief_title>HFNC vs Nasal Cannula in Mild Chronic Obstructive Pulmonary Disease Exacerbation</brief_title>
  <official_title>Comparison of High Flow Nasal Cannula vs Nasal Cannula in Mild Chronic Obstructive Pulmonary Disease Exacerbation(AECOPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China-Japan Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China-Japan Friendship Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For AECOPD patients, only 8% patients ventilated by noninvasive and invasive positive
      pressure ventilation. Nasal cannula is the most common pattern of oxygen therapy in mild
      AECOPD. As a low flow oxygen therapy, nasal cannula has many disadvantages.Therefore, we
      design a randomized controlled trial(RCT)to explore whether HFNC would be better than nasal
      cannula to prevent the aggravation of respiratory failure and endotracheal intubation in mild
      AECOPD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For AECOPD patients, most of patients don't need respiratory support, only 8% patients
      ventilated by noninvasive and invasive positive pressure ventilation. Nasal cannula is the
      most common pattern of oxygen therapy in mild AECOPD. As a low flow oxygen therapy, nasal
      cannula has many disadvantages: discomfort, low humidity and unstable fraction of inspired
      oxygen(FiO2) in inspiratory gas. Therefore, we design a RCT to explore whether HFNC would be
      better than nasal cannula to prevent the aggravation of respiratory failure and endotracheal
      intubation in mild AECOPD.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>endotracheal intubation demand rate</measure>
    <time_frame>90days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>actual endotracheal intubation rate</measure>
    <time_frame>90days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">328</enrollment>
  <condition>COPD Exacerbation</condition>
  <arm_group>
    <arm_group_label>High flow nasal cannula</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High flow nasal cannula(OptiflowTM); Flow 25-60 L/min is set according to patients' comfort; FiO2 is adjusted to maintain peripheral capillary oxygen saturation(SpO2) 90-95%; temperature is set at 37.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nasal cannula</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Nasal cannula;set oxygen flow to keep SpO2 90-95%</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High flow nasal cannula</intervention_name>
    <description>High flow nasal cannula (HFNC) is a new emerging noninvasive respiratory support technology, which mainly includes high flow (15-60 L/min) device, heating humidification device and nasal cannula for high flow. A large number of physiological studies confirmed that HFNC has the following critical physiological effects: promoting airway humidification, improving tolerance of treatment, reducing the physiological dead space on the upper respiratory tract, producing a certain level of positive end expiratory pressure (2-7 cmH2O), decreasing the work of breathing and so on.</description>
    <arm_group_label>High flow nasal cannula</arm_group_label>
    <other_name>High flow oxygen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  AECOPD; pHâ‰¥7.35, PaCO2&gt;45 mmHg

        Exclusion Criteria:

          -  Need to be intubated immediately; refuse to engage in the study; severe organ
             dysfunction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qingyuan Zhan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>China-Japan Friendship Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jingen Xia, Master</last_name>
    <phone>13466396561</phone>
    <phone_ext>+86</phone_ext>
    <email>xiajingen_00632@163.com</email>
  </overall_contact>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2016</study_first_submitted>
  <study_first_submitted_qc>December 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2016</study_first_posted>
  <last_update_submitted>December 27, 2016</last_update_submitted>
  <last_update_submitted_qc>December 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>China-Japan Friendship Hospital</investigator_affiliation>
    <investigator_full_name>Qingyuan Zhan</investigator_full_name>
    <investigator_title>head of Pulmonary and Critical care medicine ward 4</investigator_title>
  </responsible_party>
  <keyword>COPD Exacerbation</keyword>
  <keyword>High Flow Oxygen</keyword>
  <keyword>Nasal Cannula</keyword>
  <keyword>mild</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

